S
af
er
H
o
sp
it
al
s
1. Rea E., Upshur R. Semmelweis revisited: the ethics of infection prevention among health care
workers. CMAJ, 2001; 164 (10):1447- 1448.
2. Gallaguer R. Infection control: public health, clinical effectiveness and education.
Br J Nurs., 1999;8(18):1212-14.
3. Pannuti CS, Grinbaum RS. An overview of nosocomial infection control in Brazil. Infect Control Hosp
Epidemiol. 1995 Mar;16(3):170-4.
4. ANVISA. Curso Básico de Controle de Infecção Hospitalar. Brasília, 2000.
5. Hoeffel et al. Controle e prevenção de infecções – custos e economia. Jan., 2005.
http://www.cih.com.br/custos.htm#l1
6. Beggs CB. The airborne transmition of infection hospital buildings: fact or fiction? Indoor and Built
Environment, 2003;12:9-18.
7. Beggs CB. Engineering the control of airborne pathogens. School of Civil Engineering, University of
Leeds, Leeds LS2 9JT, UK.
8. Zavascki AP, Cruz RP, Goldani LZ. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a
comparative analysis of two case–control studies in hospitalized patients. Journal of Hospital
Infection,2005;59(2):96-101.
9. Sader HS, Gales AC, Pfaller MA, Mendes RE, Zoccoli C, Barth A, Jones RN. Pathogen frequency and
resistance patterns in brazilian hospitals: summary of results from three years of the SENTRY
antimicrobial surveillance program. Braz J Infect Dis vol.5 no.4 Salvador Aug. 2001.
10. Trindade, P. A., McCulloch, J.A., Oliveira, G.A., Mamizuka, E.M. Molecular Techniques for MRSA
Typing: Current Issues and Perspectives. The Brazilian Journal of Infectious Diseases., 2003;7(1):32-
43
11. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the
United States. 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis.
1993;167:1247-1251.
12. Maschmeyer G, Ruhnke M. Update on antifungal treatment of invasive Candida and Aspergillus
infections. Mycoses., 2004;47(7):263-76.
13. Warris A, Voss A, verwij PE., Hospital sources of Aspergillus species: New routes of transmission?
Rev Iberoam Mocol, 2001, 18:156-162.
14. Richardson MD & Ellis M.. Clinical and laboratory diagnosis of systemic fungal infection. Hospital
Medicine, 2000; 61: 610-614.
15. Brochura médica de divulgação medicamento V-Fend da Pfizer - 2004.
16. Lacerda RA. Infecções Hospitalares no Brasil. Tese de Doutorado, USP – Departamento de
Enfermagem, 1995.
17. Starling CE, Couto BR, Pinheiro SM. Applying the Centers for Disease Control and Prevention and
National Nosocomial Surveillance system methods in Brazilian hospitals. Am J Infect Control., 1997;
25(4):303-11.
18. Lepock JR. Role of nuclear protein denaturation and aggregation in thermal radiosensitization. Int J
Hyperthermia. 2004 Mar;20(2):115-30.
19. Lepock JR. Cellular effects of hyperthermia: relevance to the minimum dose for thermal damage. Int
J Hyperthermia. 2003 May-Jun;19(3):252-66.
20. Consulta Pública 109 / 2003
Efficient:
Airfree is tested in real working environments with people in them
by credible ISO 17025 independent laboratories and universities in several
countries.Airfree destroys any microorganism such as mold spores, bacteria,
viruses, and dust mite allergens when passing through its patented high
efficiency thermo dynamic sterilizing ceramic core known as ThermoDyn
regardless of how hazardous and small they might be.
Silent:
No sound emission.
Exclusive:
Airfree uses just heat ThermoDyn technology to destroy and
incinerate airborne microorganisms. No fiber glass filters, triclosan coated
paper or any kind of material that can be harmful to
those operating or wasting it.
Ozone Reduction:
Airfree exclusive
ThermoDyn technology is the only
one reducing ozone while
destroying microorganisms.
Economic:
Airfree model
electric consumption is lower
that a 50W light bulb. No
replacement parts required like
filters that may cost hundreds of
dollars a year.
Easy Installation:
Just place
Airfree on the floor and plug it into
the nearest electric outlet. No need for
maintenance or special cleaning.
®
Bibliographical References
Healthier
Healthier
Airfree P models
